Proteomic biomarkers in body fluids associated with pancreatic cancer

Cristina Jimenez-Luna, Carolina Torres, Raul Ortiz, Carmelo Dieguez, Joaquina Martinez-Galan, Consolacion Melguizo, Jose C Prados and Octavio Caba _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:16573-16587. https://doi.org/10.18632/oncotarget.24654

Metrics: PDF 1764 views  |   HTML 5460 views  |   ?  


Cristina Jimenez-Luna1, Carolina Torres2, Raul Ortiz3, Carmelo Dieguez4, Joaquina Martinez-Galan5, Consolacion Melguizo1, Jose C. Prados1 and Octavio Caba3

1Institute of Biopathology and Regenerative Medicine (IBIMER), Granada University, Granada, Spain

2Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, IL, USA

3Department of Health Sciences, Jaen University, Jaen, Spain

4Department of Gastroenterology, San Cecilio University Hospital, Granada, Spain

5Department of Oncology, Virgen de Las Nieves University Hospital, Granada, Spain

Correspondence to:

Octavio Caba, email: [email protected]

Keywords: proteomics; pancreatic cancer; biomarker; body fluids; diagnosis

Received: December 23, 2017     Accepted: February 25, 2018     Published: March 27, 2018


Pancreatic cancer (PC) is a highly malignant disease that represents the fourth leading cancer-related death worldwide. There has been very little improvement in survival rates over recent years, and surgical resection remains the only reliable curative approach. Factors that contribute to this dismal prognosis for PC include its rapid progression and invasion, the absence of specific symptoms, and the little impact of available chemotherapy. Importantly, the management of this malignancy is also limited by the lack of highly specific and sensitive biomarkers for its diagnosis and follow-up, and their identification is therefore considered a promising strategy to improve outcomes in these patients. Numerous translational studies have explored the usefulness of body fluids as a non-invasive source of PC-specific biomarkers, and innovations in proteomic methods and technologies have provided a myriad of protein biomarkers for different cancers. The adoption of a proteomic approach has improved understanding of the biology of PC and contributed to the potential identification of protein biomarkers for this disease. This review considers the most recent research efforts to develop novel proteomic biomarkers in body fluids for PC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24654